An Open-Label, Expanded Access Study of Cabozantinib (XL184) in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Phase of Trial: Phase III
Latest Information Update: 15 Jan 2013
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Exelixis
- 15 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2013 Planned end date (30 Jun 2013) added as reported by Oregon Health and Science University Institutional Review Board.
- 06 Jan 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board; IRB00008671).